Claims for Patent: 10,155,932

Summary for Patent: 10,155,932

Title:	Decreasing potential iatrogenic risks associated with influenza vaccines
Abstract:	Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.
Inventor(s):	Gregersen Jens-Peter
Assignee:	Novartis AG
Application Number:	US15150214
Patent Claims:

Details for Patent 10,155,932

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	August 31, 2005	10,155,932	2036-05-09
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	December 14, 2012	10,155,932	2036-05-09
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	October 05, 2006	10,155,932	2036-05-09
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	November 10, 2009	10,155,932	2036-05-09
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	August 15, 2013	10,155,932	2036-05-09
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	September 27, 2013	10,155,932	2036-05-09